Improving outcomes for neurofibromatosis 1–associated brain tumors

References

• Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993;53(2):305-13
   PubMed Web of Science ®Google Scholar
• Neurofibromatosis. Natl Inst Health Consens Dev Conf Consens Statement 1987;6(12):1-7
   Google Scholar
• Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002;4(3):105-11
   PubMed Web of Science ®Google Scholar
• DeBella K, Poskitt K, Szudek J, Friedman JM. Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 2000;54(8):1646-51
   PubMed Web of Science ®Google Scholar
• Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994;125(1):63-6
   PubMed Web of Science ®Google Scholar
• Guillamo JS, Creange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003;126(Pt 1):152-60
   PubMed Web of Science ®Google Scholar
• Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro-oncol 2012;14(6):790-7
   PubMed Web of Science ®Google Scholar
• Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001;68(5):1110-18
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Rasmussen SA, Wolkenstein P, et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 2002;59(5):759-61
   PubMedGoogle Scholar
• Rosenfeld A, Listernick R, Charrow J, Goldman S. Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 2010;26(5):663-7
   PubMedGoogle Scholar
• Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997;41(2):143-9
   PubMed Web of Science ®Google Scholar
• Stern J, Jakobiec FA, Housepian EM. The architecture of optic nerve gliomas with and without neurofibromatosis. Arch Ophthalmol 1980;98(3):505-11
   PubMedGoogle Scholar
• Chateil JF, Soussotte C, Pedespan JM, et al. MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol 2001;74(877):24-31
   PubMedGoogle Scholar
• Piccirilli M, Lenzi J, Delfinis C, et al. Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature. Childs Nerv Syst 2006;22(10):1332-7
   PubMed Web of Science ®Google Scholar
• Kluwe L, Hagel C, Tatagiba M, et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol 2001;60(9):917-20
   PubMedGoogle Scholar
• Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118(5):1739-49
   PubMed Web of Science ®Google Scholar
• Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011;121(6):763-74
   PubMed Web of Science ®Google Scholar
• Yu J, Deshmukh H, Gutmann RJ, et al. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 2009;73(19):1526-31
   PubMed Web of Science ®Google Scholar
• Blazo MA, Lewis RA, Chintagumpala MM, et al. Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet A 2004;127A(3):224-9
   PubMedGoogle Scholar
• King A, Listernick R, Charrow J, et al. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 2003;122A(2):95-9
   PubMedGoogle Scholar
• Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61(3):189-98
   PubMed Web of Science ®Google Scholar
• Fisher MJ, Avery RA, Allen JC, et al. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 2013;81(21 Suppl 1):S15-24
   Google Scholar
• Avery RA, Ferner RE, Listernick R, et al. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol 2012;110(1):1-7
   PubMedGoogle Scholar
• Avery RA, Hwang EI, Ishikawa H, et al. Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. JAMA Ophthalmol 2014;132(3):265-71
   PubMed Web of Science ®Google Scholar
• Listernick R, Charrow J, Gutmann DH. Comments on neurofibromatosis 1 and optic pathway tumors. Am J Med Genet 2001;102(1):105
   PubMedGoogle Scholar
• Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatr 1995;126(3):364-7
   PubMed Web of Science ®Google Scholar
• Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004;111(3):568-77
   PubMed Web of Science ®Google Scholar
• Diggs-Andrews KA, Brown JA, Gianino SM, et al. Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol 2014;75(2):309-16
   PubMedGoogle Scholar
• Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86(5):747-54
   PubMed Web of Science ®Google Scholar
• Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006;24(16):2570-5
   PubMed Web of Science ®Google Scholar
• Grill J, Couanet D, Cappelli C, et al. Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 1999;45(3):393-6
   PubMedGoogle Scholar
• Bilaniuk LT, Molloy PT, Zimmerman RA, et al. Neurofibromatosis type 1: brain stem tumours. Neuroradiology 1997;39(9):642-53
   PubMedGoogle Scholar
• Molloy PT, Bilaniuk LT, Vaughan SN, et al. Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 1995;45(10):1897-902
   PubMedGoogle Scholar
• Angelini P, Hawkins C, Laperriere N, et al. Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. J Neurooncol 2011;101(1):75-81
   PubMed Web of Science ®Google Scholar
• Freeman CR, Perilongo G. Chemotherapy for brain stem gliomas. Childs Nerv Syst 1999;15(10):545-53
   PubMed Web of Science ®Google Scholar
• Rodriguez FJ, Perry A, Gutmann DH, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008;67(3):240-9
   PubMedGoogle Scholar
• Vinchon M, Soto-Ares G, Ruchoux MM, Dhellemmes P. Cerebellar gliomas in children with NF1: pathology and surgery. Childs Nerv Syst 2000;16(7):417-20
   PubMedGoogle Scholar
• Leonard JR, Perry A, Rubin JB, et al. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 2006;67(8):1509-12
   PubMedGoogle Scholar
• Carret AS, Tabori U, Crooks B, et al. Outcome of secondary high-grade glioma in children previously treated for a malignant condition: a study of the Canadian Pediatric Brain Tumour Consortium. Radiother Oncol 2006;81(1):33-8
   PubMedGoogle Scholar
• Reilly KM, Loisel DA, Bronson RT, et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26(1):109-13
   PubMed Web of Science ®Google Scholar
• Reilly KM, Tuskan RG, Christy E, et al. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci USA 2004;101(35):13008-13
   PubMedGoogle Scholar
• Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8(2):119-30
   PubMed Web of Science ®Google Scholar
• Kwon CH, Zhao D, Chen J, et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 2008;68(9):3286-94
   PubMed Web of Science ®Google Scholar
• Alcantara Llaguno S, Chen J, Kwon CH, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009;15(1):45-56
   PubMed Web of Science ®Google Scholar
• Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488(7412):522-6
   PubMed Web of Science ®Google Scholar
• Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000;59(9):759-67
   PubMedGoogle Scholar
• Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003;23(26):8949-54
   PubMed Web of Science ®Google Scholar
• Anastasaki C, Gutmann DH. Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation. Hum Mol Genet 2014;23(25):6712-21
   PubMedGoogle Scholar
• Banerjee S, Crouse NR, Emnett RJ, et al. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci USA 2011;108(38):15996-6001
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Yi Y, Chen DY, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005;65(7):2755-60
   PubMed Web of Science ®Google Scholar
• Warrington NM, Woerner BM, Daginakatte GC, et al. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res 2007;67(18):8588-95
   PubMedGoogle Scholar
• Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 2005;65(1):236-45
   PubMedGoogle Scholar
• Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2013;123(1):340-7
   PubMed Web of Science ®Google Scholar
• Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68(21):8673-7
   PubMed Web of Science ®Google Scholar
• Kaul A, Chen YH, Emnett RJ, et al. Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev 2012;26(23):2561-6
   PubMed Web of Science ®Google Scholar
• Kaul A, Toonen JA, Cimino PJ, et al. Gutmann DH. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro Oncol 2014
   Google Scholar
• Karajannis MA, Legault G, Fisher MJ, et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-oncol 2014;16(10):1408-16
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431-5
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287):427-30
   PubMed Web of Science ®Google Scholar
• Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01089101&Search=Search
   Google Scholar
• Hegedus B, Banerjee D, Yeh TH, et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 2008;68(5):1520-8
   PubMed Web of Science ®Google Scholar
• Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01158651&Search=Search
   Google Scholar
• Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1). Available from: https://clinicaltrials.gov/ct2/results?term=NCT00901849&Search=Search
   Google Scholar
• Yalon M, Rood B, MacDonald TJ, et al. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer 2013;60(1):71-6
   PubMed Web of Science ®Google Scholar
• Bajenaru ML, Hernandez MR, Perry A, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003;63(24):8573-7
   PubMed Web of Science ®Google Scholar
• Warrington NM, Gianino SM, Jackson E, et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res 2010;70(14):5717-27
   PubMedGoogle Scholar
• Daginakatte GC, Gianino SM, Zhao NW, et al. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 2008;68(24):10358-66
   PubMed Web of Science ®Google Scholar
• Simmons GW, Pong WW, Emnett RJ, et al. Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. J Neuropathol Exp Neurol 2011;70(1):51-62
   PubMed Web of Science ®Google Scholar
• Pong WW, Higer SB, Gianino SM, et al. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol 2013;73(2):303-8
   PubMed Web of Science ®Google Scholar
• Sikkema AH, de Bont ES, Molema G, et al. Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol 2011;37(5):538-48
   PubMedGoogle Scholar
• Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009;52(7):791-5
   PubMed Web of Science ®Google Scholar
• Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 2013;60(5):776-82
   PubMed Web of Science ®Google Scholar
• Warren KE, Goldman S, Pollack IF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 2011;29(3):324-9
   PubMed Web of Science ®Google Scholar
• Brown JA, Gianino SM, Gutmann DH. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci 2010;30(16):5579-89
   PubMed Web of Science ®Google Scholar
• Sharif S, Upadhyaya M, Ferner R, et al. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet 2011;48(4):256-60
   PubMedGoogle Scholar
• Ars E, Kruyer H, Morell M, et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet 2003;40(6):e82
   Google Scholar
• Amlin-Van Schaick J, Kim S, Broman KW, Reilly KM. Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5. Mamm Genome 2012;23(3-4):277-85
   PubMedGoogle Scholar
• Amlin-Van Schaick JC, Kim S, DiFabio C, et al. Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. Neuro-oncol 2012;14(2):160-74
   PubMedGoogle Scholar
• Diggs-Andrews KA, Brown JA, Gianino SM, et al. Reply: to PMID 24375753. Ann Neurol 2014;75(5):800-1
   PubMedGoogle Scholar
• Fisher MJ, Loguidice M, Gutmann DH, et al. Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol 2014;75(5):799-800
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs 2013;22(4):443-62
   PubMed Web of Science ®Google Scholar